People | October 04, 2022
Matt Sause elevated as new CEO of Roche Diagnostics
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Almost 300 million people globally have chronic hepatitis B
Subscribe To Our Newsletter & Stay Updated
